Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Last update - 15.59pm 01/10/2024 (20 minute delay)
?
Day | ||||||||
---|---|---|---|---|---|---|---|---|
Open | 23.5¢ | Day High | 29.8¢ | Day Low | 23.5¢ | |||
Daily Volume | 4768043 |
Bids | Sellers | |||||
---|---|---|---|---|---|---|
Number | Price | Volume | Number | Price | Volume | |
1 | 28.5¢ | 26319 | 1 | 29.0¢ | 33984 |
Directors & Senior Management
Mr. Richard Homsany | Executive Chairman of the Board |
Ms. Katherine Garvey | Company Secretary |
Mr. Michel Marier | Non Executive Director |
Mr. Richard J. Patricio | Non Executive Director |
Data source: Refinitiv